Regeneron Pharmaceuticals, Inc. (REGN) AI Stock Analysis

Established in 1988 and headquartered in Tarrytown, New York, Regeneron Pharmaceuticals, Inc. is a biotechnology company engaged in the discovery, development, and commercialization of transformative medicines worldwide. Its commercial product portfolio features EYLEA, which treats neovascular age-related macular degeneration and diabetic retinopathy, and Dupixent, used for atopic dermatitis and asthma in adult and pediatric populations. Regeneron also developed the REGEN-COV therapy for COVID-19. The company maintains an extensive research pipeline spanning eye diseases, allergic and inflammatory conditions, cardiovascular disorders, infectious diseases, and rare genetic conditions, supported by collaborations with Sanofi, Bayer, Roche, government entities, and academic institutions.

Regeneron recorded a 5-year revenue CAGR of 11.0% from FY2020 to FY2025. Annual revenue shifted from $16.07B in FY2021 to $12.17B in FY2022, before rising to $13.12B in FY2023, $14.20B in FY2024, and $14.34B in FY2025. Over this period, net income moved from $8.08B in FY2021 to $4.50B in FY2025, while gross margin stood at 85.4% and operating margin was 24.9% in FY2025. Over the trailing twelve months, revenue reached $15.53B with a net profit margin of 27.9% and operating margin of 33.1%. In the latest quarter ended June 30, 2026, quarterly revenue grew 16.7% year-over-year, while quarterly earnings declined 4.5%.

As of June 30, 2026, Regeneron held $7.99B in cash and short-term investments against total debt of $1.99B, resulting in net cash of $6.01B. The company reported a current ratio of 3.34 and a debt-to-equity ratio of 0.06 on shareholders' equity of $31.71B. In FY2025, operating cash flow reached $4.98B and free cash flow was $4.08B. Capital expenditures were $898.4M, while the company repurchased $3.97B in shares and paid $370.3M in dividends.

Regeneron trades at a trailing P/E of 19.6x and a forward P/E of 14.5x, compared to the median of its Nasdaq-100 Healthcare peers of 34.1x and 23.0x, respectively. Its price-to-sales ratio of 5.2x and EV/EBITDA of 13.1x are also below peer medians of 6.5x and 24.5x. Over the past 1-year period, REGN gained 39.6%, outperforming the S&P 500 return of 16.8%. Over a 5-year period, the stock returned 44.3%, trailing the S&P 500 return of 83.0%.

Regeneron pays a quarterly dividend with an annual forward dividend of $3.76, representing a dividend yield of 0.48% and a payout ratio of 8.2%. The company has paid dividends for 2 consecutive years, and its last ex-dividend date was August 18, 2026. In FY2025, total dividends paid were $370.3M.

Wall Street analysts maintain 15 Strong Buy, 4 Buy, 8 Hold, and 1 Sell ratings on Regeneron. The mean price target is $863.93, indicating 9.3% upside from the last close of $790.74 on October 16, 2026. For the fiscal year ending December 31, 2026, consensus estimates project EPS of $57.84 and revenue of $17.46B. The company beat EPS estimates in each of the last 4 quarters, and its next earnings date is October 30, 2026.

This page is an AI-written research summary of Regeneron Pharmaceuticals, Inc. (REGN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: REGN income statement, REGN balance sheet, REGN key metrics, REGN analyst forecast, REGN chart. See the REGN stock overview for the latest quote and news.